(Q36581588)

15 August 2017

1 reference

title

Hepatitis C virus entry: molecular biology and clinical implications (English)

1 reference

15 August 2017

1 reference

0 references

1 reference

3

Thomas F Baumert

1 reference

15 August 2017

1

Heidi Barth

1 reference

15 August 2017

T Jake Liang

2

1 reference

PubMed ID

16941688

15 August 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

15 August 2017

1 reference

15 August 2017

44

1 reference

15 August 2017

527-535

1 reference

15 August 2017

3

1 reference

Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines

15 August 2017

1 reference

Structural characterization of human liver heparan sulfate.

21 January 2018

1 reference

Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation

21 January 2018

1 reference

Effect of immune globulin on the prevention of experimental hepatitis C virus infection

21 January 2018

1 reference

Unscrambling hepatitis C virus-host interactions

21 January 2018

1 reference

7 January 2021

Challenges and successes in developing new therapies for hepatitis C.

1 reference

7 January 2021

Transmission of hepatitis C virus infection to tree shrews

1 reference

7 January 2021

Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection

1 reference

7 January 2021

Evidence of viral replication in circulating dendritic cells during hepatitis C virus infection

1 reference

7 January 2021

Dendritic cell susceptibility to hepatitis C virus genotype 1 infection

1 reference

7 January 2021

How Viruses Enter Animal Cells

1 reference

7 January 2021

Alpha Interferon Inhibits Hepatitis C Virus Replication in Primary Human Hepatocytes Infected In Vitro

1 reference

7 January 2021

Scavenger receptor class B type I and hepatitis C virus infection of primary tupaia hepatocytes.

1 reference

7 January 2021

Binding of hepatitis C virus to CD81

1 reference

7 January 2021

The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus

1 reference

7 January 2021

Hepatitis C virus structural proteins assemble into viruslike particles in insect cells

1 reference

7 January 2021

Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles

1 reference

7 January 2021

Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes

1 reference

7 January 2021

Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins

1 reference

7 January 2021

Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

1 reference

7 January 2021

Complete replication of hepatitis C virus in cell culture

1 reference

7 January 2021

Robust hepatitis C virus infection in vitro

1 reference

7 January 2021

Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate

1 reference

7 January 2021

Uptake and presentation of hepatitis C virus-like particles by human dendritic cells

1 reference

7 January 2021

Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C.

1 reference

7 January 2021

Interaction of hepatitis C virus-like particles and cells: a model system for studying viral binding and entry

1 reference

7 January 2021

Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding

1 reference

7 January 2021

Neutralizing antibody response during acute and chronic hepatitis C virus infection

1 reference

7 January 2021

Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection

1 reference

7 January 2021

Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1

1 reference

7 January 2021

In vitro assay for neutralizing antibody to hepatitis C virus: Evidence for broadly conserved neutralization epitopes

1 reference

7 January 2021

Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity

1 reference

7 January 2021

Coexpression of hepatitis C virus E1 and E2 chimeric envelope glycoproteins displays separable ligand sensitivity and increases pseudotype infectious titer

1 reference

7 January 2021

Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro

1 reference

7 January 2021

Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells

1 reference

7 January 2021

Structural biology of hepatitis C virus

1 reference

7 January 2021

Monoclonal Antibody AP33 Defines a Broadly Neutralizing Epitope on the Hepatitis C Virus E2 Envelope Glycoprotein

1 reference

7 January 2021

Analysis of a Highly Flexible Conformational Immunogenic Domain A in Hepatitis C Virus E2

1 reference

7 January 2021

Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions

1 reference

7 January 2021

Characterization of functional hepatitis C virus envelope glycoproteins.

1 reference

7 January 2021

Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins

1 reference

7 January 2021

Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor

1 reference

7 January 2021

Basic residues in hypervariable region 1 of hepatitis C virus envelope glycoprotein e2 contribute to virus entry

1 reference

7 January 2021

A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells

1 reference

7 January 2021

Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity

1 reference

7 January 2021

Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR

1 reference

7 January 2021

L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus

1 reference

7 January 2021

DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2

1 reference

7 January 2021

Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor

1 reference

7 January 2021

CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system

1 reference

7 January 2021

CD81 is an entry coreceptor for hepatitis C virus

1 reference

7 January 2021

CD81 is required for hepatitis C virus glycoprotein-mediated viral infection

1 reference

7 January 2021

Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner

1 reference

7 January 2021

Characterization of the Early Steps of Hepatitis C Virus Infection by Using Luciferase Reporter Viruses

1 reference

7 January 2021

Binding of hepatitis C virus E2 glycoprotein to CD81 does not correlate with species permissiveness to infection

1 reference

7 January 2021

Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems

1 reference

7 January 2021

Analysis of the binding of hepatitis C virus genotype 1a and 1b E2 glycoproteins to peripheral blood mononuclear cell subsets

1 reference

7 January 2021

Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus

1 reference

7 January 2021

High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I.

1 reference

7 January 2021

Hepatitis C virus entry: potential receptors and their biological functions

1 reference

7 January 2021

Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells

1 reference

7 January 2021

Characterization of Low- and Very-Low-Density Hepatitis C Virus RNA-Containing Particles

1 reference

7 January 2021

An Interplay between Hypervariable Region 1 of the Hepatitis C Virus E2 Glycoprotein, the Scavenger Receptor BI, and High-Density Lipoprotein Promotes both Enhancement of Infection and Protection against Neutralizing Antibodies

1 reference

7 January 2021

Heparan sulphate proteoglycans: the sweet side of development

1 reference

7 January 2021

Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption

1 reference

7 January 2021

The hypervariable region 1 of the E2 glycoprotein of hepatitis C virus binds to glycosaminoglycans, but this binding does not lead to infection in a pseudotype system

1 reference

7 January 2021

DC-SIGN: escape mechanism for pathogens

1 reference

7 January 2021

L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus

1 reference

7 January 2021

C-type lectins L-SIGN and DC-SIGN capture and transmit infectious hepatitis C virus pseudotype particles

1 reference

7 January 2021

Flavivirus structure and membrane fusion

1 reference

7 January 2021

Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation

1 reference

7 January 2021

Functional hepatitis C virus envelope glycoproteins

1 reference

7 January 2021

A model for the hepatitis C virus envelope glycoprotein E2.

1 reference

7 January 2021

Hepatitis C virus glycoproteins mediate low pH-dependent membrane fusion with liposomes

1 reference

7 January 2021

Time- and Temperature-Dependent Activation of Hepatitis C Virus for Low-pH-Triggered Entry

1 reference

7 January 2021

Signalling in viral entry

1 reference

7 January 2021

Host cell responses induced by hepatitis C virus binding.

1 reference

7 January 2021

Inhibition of Natural Killer Cells through Engagement of CD81 by the Major Hepatitis C Virus Envelope Protein

1 reference

7 January 2021

Binding of the Hepatitis C Virus Envelope Protein E2 to CD81 Inhibits Natural Killer Cell Functions

1 reference

7 January 2021

Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-stimulatory signal for human T cells

1 reference

7 January 2021

Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders

1 reference

7 January 2021

Hepatitis C virus E2-CD81 interaction induces hypermutation of the immunoglobulin gene in B cells

1 reference

7 January 2021

Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization

1 reference

7 January 2021

Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein

1 reference

7 January 2021

Five-year follow-up of patients with primary antibody deficiencies following an outbreak of acute hepatitis C

1 reference

7 January 2021

Humoral immune response in acute hepatitis C virus infection

1 reference

7 January 2021

HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites

1 reference

7 January 2021

Antibody neutralization and escape by HIV-1

1 reference

7 January 2021

High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI.

1 reference

7 January 2021

Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33.

1 reference

7 January 2021

Diagnostic tests for hepatitis C.

1 reference

7 January 2021

Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma

1 reference

7 January 2021

Preclinical Evaluation of Two Neutralizing Human Monoclonal Antibodies against Hepatitis C Virus (HCV): a Potential Treatment To Prevent HCV Reinfection in Liver Transplant Patients

1 reference

7 January 2021

Lack of Protective Immunity Against Reinfection with Hepatitis C Virus

1 reference

7 January 2021

Neutralizing antibodies against HIV -- back in the major leagues?

1 reference

7 January 2021

Antiviral effect of the heparan sulfate mimetic, PI-88, against dengue and encephalitic flaviviruses

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.21321

1 reference

15 August 2017

1 reference

PubMed ID

16941688